1. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371(7):624–34. 2. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(14):1823–38. 3. Perkovic V, Agarwal R, Fioretto P, Hemmelgarn BR, Levin A, Thomas MC, et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90(6):1175–83. 4. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1). 5. Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia [Internet]. 2016;59(11):2298–307. Available from: http://dx.doi.org/10.1007/ s00125-016-4065-6 6. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. N Engl J Med [Internet]. 2001 Sep 20;345(12):870–8. Available from: https://doi.org/10.1056/ NEJMoa011489 7. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes. Diabetes Care [Internet]. 2007 Jun 1;30(6):1577 LP – 1578. Available from: http://care. diabetesjournals.org/content/30/6/1577.abstract 8. Hunsicker LG, Atkins RC, Lewis JB, Braden G, Champion De Crespigny PJ, DeFerrari G, et al. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl. 2004;66(92):99–101. 9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med [Internet]. 2001 Sep 20;345(12):861–9. Available from: https://doi.org/10.1056/ NEJMoa011161 10. Strippoli GFM, Bonifati C, Craig ME, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev [Internet]. 2006;(4). Available from: https:// doi.org//10.1002/14651858.CD006257 11. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med. 2000;160(5):685–93. 12. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):542–51. 13. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, et al. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):333–44. 14. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term benefits of intensive glucose Control for preventing endstage kidney disease: ADVANCE-ON. Diabetes Care. 2016;39(5):694– 700. 15. Roussel R, Lorraine J, Rodriguez A, Salaun-Martin C. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. Adv Ther. 2015;32(11):1029–64. 16. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–65. 17. Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: A systematic review. Ann Intern Med. 2017;166(3):191–200. 18. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, et al. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol. 2018;46(6):462–72. 19. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA - J Am Med Assoc. 2019;321(1):69–79. 20. Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. J Am Soc Nephrol. 2017;28(8):2263–74. 21. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes : A systematic review and metaanalysis. JAMA – J Am Med Assoc. 2015;313(6):603–15. 22. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Biostat M, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392–406. 23. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Eff ects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet [Internet]. 2016;387(10017):435–43. Available from: http://dx.doi. org/10.1016/S0140-6736(15)00805-3 24. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. JAC [Internet]. 2010;56(1):77–85. Available from: http://dx.doi.org/10.1016/j.jacc.2010.02.046 25. Fitchett D, Bluhmki E, Ph D, Hantel S, Ph D, Mattheus M, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. 2015;2117–28. 26. W. MK, Bruce N, Vlado P, Dick de Z, Greg F, Ngozi E, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation [Internet]. 2018 Jan 23;137(4):323–34. Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.032038 27. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med [Internet]. 2018 Nov 10;380(4):347–57. Available from: https://doi. org/10.1056/NEJMoa1812389 28. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med [Internet]. 2016 Jun 13;375(4):311–22. Available from: https://doi.org/10.1056/NEJMoa1603827 29. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med [Internet]. 2016 Sep 15;375(19):1834–44. Available from: https://doi.org/10.1056/NEJMoa1607141